Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 67. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-03-01 to 2025-03-01.)
ArticleCitations
Double Duty1004
Correction to Lancet Gastroenterol Hepatol 2022; 7: 152–60364
Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply335
ESWL pancreatitis: yet another post-procedural pancreatitis to worry about?335
Improving liver cancer care across Europe333
Interim evaluation of the colorectal cancer screening programme in the Netherlands327
Trends in alcohol-specific deaths in the UK and industry responses287
Controversy over colonoscopy for colorectal cancer screening272
Global burden of occult hepatitis B virus infection: where we are and what to do267
Procalcitonin-guided reduction of antibiotic use in acute pancreatitis259
Comparison of trends in early-onset colorectal cancer in North America and Europe – Authors' reply221
Comparison of trends in early-onset colorectal cancer in North America and Europe211
Standardising early liver transplantation for severe alcohol-related hepatitis – Authors' reply199
Disparities in gastroenterology grand rounds speakerships in the USA195
USPSTF: colorectal cancer screening in the US from 45 years189
Challenging stigma around alcohol misuse176
Research in Brief175
Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review170
Correction to Lancet Gastroenterol Hepatol 2021; 6: 875170
Lessons from a trial of colesevelam for bile acid diarrhoea167
Virtual ESMO World Congress on Gastrointestinal Cancer 2021158
Outcomes of minimum unit pricing for alcohol in Scotland156
A personalised taper-to-target strategy with adalimumab in Crohn's disease155
Immune checkpoint inhibitors in colorectal cancer: dream and reality153
Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial152
Viral hepatitis in Asia-Pacific: a post-COVID-19 reset146
The quest for the ideal NASH biomarker145
Research in Brief145
Predicting clinical outcomes in people with NAFLD: no need for a crystal ball?134
Correction to Lancet Gastroenterol Hepatol 2021; 6: 933–46133
Alcohol-related harms and the case for minimum unit pricing123
Vedolizumab in paediatric IBD: a huge step forward but not there yet116
Flux Gourmet: a visual feast with a starved social mission116
Séverine Vermeire: advancing patient-centred research in IBD110
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply109
Living108
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection104
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern?104
Research in Brief102
How can I improve my gut health if I am on a special diet?98
Ensuring patients with malignant bowel obstruction are central in research and clinical decisions98
Ingestion of high-power magnets: cause for concern97
Correction to Lancet Gastroenterol Hepatol 2021; 6: 569–7796
Launch of the UN Group of Friends to eliminate hepatitis89
Research in Brief88
The Liver Meeting 202386
Endoscopic screening for oesophageal cancer: empowering artificial intelligence with a high-quality examination85
Research in Brief84
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand83
New WHO guidance for country validation of viral hepatitis B and C elimination81
A whole-food exclusion diet as monotherapy for Crohn's disease80
Research in Brief80
Reducing disparities in training in inflammatory bowel disease79
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial78
The HEPSANET score to assess treatment eligibility of chronic hepatitis B in Africa78
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply75
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply75
Oral faecal microbiota transplantation in ulcerative colitis – Authors' reply74
Research in Brief73
The Other Dark Matter73
Terlipressin for hepatorenal syndrome: opportunities and challenges73
Can genetically engineered pig livers offer patients precious time?71
Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa71
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium70
Gavi's green light for hepatitis B birth dose vaccination in Africa70
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas69
Oral faecal microbiota transplantation in ulcerative colitis68
0.10780191421509